MicroRNAs miR-21a and miR-93 are down regulated in peripheral blood mononuclear cells (PBMCs) from patients with type 1 diabetes

Salas-Pérez, Francisca; Codner, Ethel; Valencia, Elizabeth; Pizarro, Carolina; Carrasco, Elena; Pérez-Bravo, Francisco

doi:10.1016/j.imbio.2012.08.276

Cited by 96 publications

(62 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The study also showed that the miR-146 levels were associated with ongoing islet autoimmunity. 64 Moreover, miR-21a and miR-93 are decreased in PBMCs from T1D patients; 65 both miRNAs have been reported to participate in inflammatory and apoptosis signaling pathways 39 and are not affected by glucose stimuli. 65 Thus, the two miRNAs might be involved in the autoimmune responses of T1D.…”

Section: Mirnas: Regulators Of Immune Pathogenesis In T1dmentioning

confidence: 99%

“…64 In addition, miR-21a and miR-93 are downregulated in the PBMCs of T1D patients compared with healthy individuals. 65 In addition to controlling gene expression in blood cells, many miRNAs are also detected in serum or plasma and other body fluids (that is, urine, saliva and breast milk) in association with microparticles, such as microvesicles or exosomes, or with proteins (for example, Argo-2). Although the functions of these miRNAs remain obscure, circulating miRNAs can serve as potential biomarkers for the detection of various forms of cancers and autoimmune diseases.…”

Section: Mirnas: Participants In Autoimmunity-mediated β-Cell Damagementioning

confidence: 99%

See 1 more Smart Citation

miRNAs: novel regulators of autoimmunity-mediated pancreatic β-cell destruction in type 1 diabetes

2017

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are a series of conserved, short, non-coding RNAs that modulate gene expression in a posttranscriptional manner. miRNAs are involved in almost every physiological and pathological process. Type 1 diabetes (T1D) is an autoimmune disease that is the result of selective destruction of pancreatic β-cells driven by the immune system. miRNAs are also important participants in T1D pathogenesis. Herein, we review the most recent data on the potential involvement of miRNAs in T1D. Specifically, we focus on two aspects: the roles of miRNAs in maintaining immune homeostasis and regulating β-cell survival and/or functions in T1D. We also discuss circulating miRNAs as potent biomarkers for the diagnosis and prediction of T1D and investigate potential therapeutic approaches for this disease.

show abstract

Section: Mirnas: Regulators Of Immune Pathogenesis In T1dmentioning

confidence: 99%

Section: Mirnas: Participants In Autoimmunity-mediated β-Cell Damagementioning

confidence: 99%

miRNAs: novel regulators of autoimmunity-mediated pancreatic β-cell destruction in type 1 diabetes

2017

View full text Add to dashboard Cite

show abstract

“…Studies revealed a different miRNA pattern in serum of type 1 diabetic patients compared with healthy individuals [35], as well as in plasma [36,37] and urine [36]. Furthermore, the miRNA content of different types of blood cells were also deregulated in type 1 and type 2 diabetic patients compared with controls [38][39][40][41][42]. Finally, analysis of circulating miRNAs in women with gestational diabetes mellitus has revealed that in both serum and plasma some miRNAs have an altered profile compared with those in control women [43,44].…”

Section: Circulating Mirnas As Biomarkers Of the Diabetic Conditionmentioning

confidence: 99%

Circulating microRNAs and diabetes: potential applications in medical practice

et al. 2015

View full text Add to dashboard Cite

The explosive increase in the worldwide prevalence of diabetes over recent years has transformed the disease into a major public health concern. While diabetes can be screened for and diagnosed by reliable biological tests based on blood glucose levels, by and large there are no means of detecting at-risk patients or of following diabetic complications. The recent discovery that microRNAs are not only chief intracellular players in many biological processes, including insulin secretion and action, but are also circulating, has put them in the limelight as possible biological markers. Here we discuss the potential role of circulating microRNAs as biomarkers in the context of diabetes and its associated complications.

show abstract

“…Indeed, the islets of T2D donors were found to display an up-regulation of miR-187 [26] and the down- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 Obesity and insulin resistance are also leading to a strong dysregulation of the miRNA profile in adipose tissue, liver and in skeletal muscles. The most affected miRNAs, including among others miR-29, miR-103/107, miR-143, miR-802 and Let-7, were shown to target key components of the insulin signaling pathway and to contribute to the loss of insulin sensitivity observed in obese individuals [28][29][30]. Moreover, miR-133 and miR-1 dysregulation has been shown to contribute to impaired muscle function in T2D [31][32][33].…”

mentioning

confidence: 99%

Therapeutic potential of miRNAs in diabetes mellitus

Henaoui

Stoll

Tugay

et al. 2014

Expert Review of Endocrinology & Metabolism

View full text Add to dashboard Cite

SummaryMicroRNAs are major regulators of gene expression that are emerging as central players in the development of many human diseases, including diabetes mellitus. In fact, diabetes manifestation is associated with alterations in the microRNA profile in insulin-secreting cells, insulin target tissues and, in case of long-term diabetes complications, in many additional organs. Diabetes results also in changes in the profile of microRNAs detectable in blood and other body fluids. This has boosted an ever increasing interest in the use of circulating microRNAs as potential biomarkers to predict the development of diabetes and its devastating complications. Moreover, promising approaches to correct the level of selected microRNAs are emerging, permitting to envisage new therapeutic strategies to treat diabetes and its complications.Key words: Diabetes mellitus; Insulin; pancreatic islet; microRNA; Gene expression; biomarker; diabetic complication; Adeno-associated virus 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 of target mRNAs that are initially recognized through base pairing to a conserved "seed" sequence corresponding to nucleotides 2-8 of the miRNAs, leading to inhibition of mRNA translational and/or to a decrease in messenger stability [2, 3]. A single miRNA typically controls hundreds of targets and each mRNA can be targeted by different miRNAs, conferring to this class of non-coding RNA molecules a huge regulatory potential [4]. In the past decade, a large body of evidence has been accumulated pointing to a role for miRNAs in the etiology and pathogenesis of diabetes and its complications. Indeed, alterations in the level of these non-coding RNAs has been observed both in insulin-secreting cells and in insulin-target tissues isolated from diabetes animal models or diabetic patients [5]. Moreover, changes in miRNA expression have been associated with long-term diabetes complications including neuropathy, retinopathy, renal failure and macrovascular diseases. Page 1 of 36 Expert Review of Endocrinology & MetabolismThe first demonstration of the involvement of miRNAs in the control of specialized β-cell functions has been provided ten years ago by Poy et al. who showed that inappropriate levels of miR-375, one of the most abundant miRNAs present in β-cells, can affect insulin secretion [6]. Later on, this and several other miRNAs including miR-15a/b, miR-16, miR-195, miR-503, miR-451, miR-214, miR-9, miR-124a, miR-7 and miR-376 were demonstrated to play important roles in the differentiation of pancreatic islet cells [7][8][9][10][11][12]. Moreover, changes in the levels of many miRNAs, including miR-9, miR...

show abstract

MicroRNAs miR-21a and miR-93 are down regulated in peripheral blood mononuclear cells (PBMCs) from patients with type 1 diabetes

Cited by 96 publications

References 23 publications

miRNAs: novel regulators of autoimmunity-mediated pancreatic β-cell destruction in type 1 diabetes

miRNAs: novel regulators of autoimmunity-mediated pancreatic β-cell destruction in type 1 diabetes

Circulating microRNAs and diabetes: potential applications in medical practice

Therapeutic potential of miRNAs in diabetes mellitus

Contact Info

Product

Resources

About